Biocept, Inc. (BIOC)

Market Cap	1.28M
Revenue (ttm)	11.38M
Net Income (ttm)	-32.23M
Shares Out	592.91K
EPS (ttm)	-56.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	318,522
Open	2.15
Previous Close	2.32
Day's Range	2.05 - 2.39
52-Week Range	2.05 - 47.70
Beta	0.92
Analysts	n/a
Price Target	n/a
Earnings Date	May 10, 2023

About BIOC

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSC...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Feb 5, 2014
• Employees: 50
• Stock Exchange: NASDAQ
• Ticker Symbol: BIOC

Financial Performance

In 2022, Biocept's revenue was $25.86 million, a decrease of -57.78% compared to the previous year's $61.25 million. Losses were -$32.09 million, 1036.2% more than in 2021.